Orange Grove Bio (“OGB”) is a preclinical drug investment and development platform focused on driving down the cost of drug discovery and advancing therapies into clinical trials.

Pre-Clinical FOCUS

Preclinical development is one of the most attractive areas for healthcare investing today. 

Investment Capabilities

Rather than focusing on opportunities in the biotech hubs,  Orange Grove Bio builds close relationships with leading research universities across the country.

Development Platform

We are unique in that we have both an investment team and an R&D and operations team. 

 Patient-Centric Mission 

Our flexible model allows us to source technology through investments in technology coming out of universities as well as through free-standing biotech companies

  • Grey LinkedIn Icon

Meet The Team


Marc Appel

  • Grey LinkedIn Icon

Marc Appel is the CEO of Orange Grove Bio, a biotech platform focused on the investment in and development of preclinical stage assets.

Ryan Fox

  • Grey LinkedIn Icon

Ryan is the Head of R&D and Operations at Orange Grove Bio.

Read more about the team right here
LG Headshot 200103_edited_edited.jpg

Lutz Giebel

  • Grey LinkedIn Icon

Dr. Lutz Giebel, the executive chairman of Orange Grove Bio, a Biotech Entrepreneur based in the San Francisco Bay Area.